Pay in 4 interest-free payments of $5.95 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Based on the outsized demand, its unlikely prices will fall anytime soon
Safety in patients with existing mild-moderate liver disease Correlation between weight loss and estimated liver fat reduction TRIUMPH-2 (Ongoing, Expected 2026) Primary Endpoints: Weight loss in diabetic patients HbA1c reduction Secondary Endpoints (Liver): Liver enzymes Metabolic markers Diabetic Population Note: Higher prevalence of MASLD/NASH (~40-50%), so liver benefits particularly important in this group
TRIUMPH-1 is complete, and several other Phase 3 trials have now reported topline results
While standard therapeutic doses have demonstrated cardiovascular and metabolic benefits in large clinical trials, the concept of using low dose GLP-1 for inflammation remains investigational, with no established FDA indication or standardized dosing protocols
US$ 22.95
US$ 29.05
US$ 20.52
US$ 29.93
